ReviewCurrent diabetes reports2011
Adipose tissue dysfunction in polycystic ovary syndrome.
Review in Current diabetes reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Prevalence of Polycystic Ovary Syndrome in Patients With Pediatric Type 2 Diabetes: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones.Frontiers in endocrinology · 2022Pooled it
- Trial
- Impaired adipogenesis and lipid storage capacity in subcutaneous adipose tissue of patients with PMOS.JCI insight · 2026Article
- Clinical Obesity and Insulin Resistance Assessed Based on SHBG Levels and HOMA-IR, TyG-Waist Circumference (TyG-WC), TyG-Waist to Height Ratio (TyG-WHtR), and TyG-Waist to Hip Ratio (TyG-WHR) Values in Young Caucasian Women with Polyendocrine Metabolic Ovarian Syndrome (PMOS).Journal of clinical medicine · 2026Article
- Expression of asprosin and OLFR734 in reproductive tissues of polycystic ovary syndrome mice: insights into metabolic and reproductive dysfunction.Cell and tissue research · 2026Article
- Role of Adipokines in the Development of Metabolic Syndrome in Patients With Polycystic Ovary Syndrome.Cureus · 2025Article
- Article
- New concepts in the roles of AMPK in adipocyte stem cell biology.Essays in biochemistry · 2024Review
- The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Pathophysiology to Diagnosis and Treatment.Medicina (Kaunas, Lithuania) · 2024Review
- Reproductive risk factors across the female lifecourse and later metabolic health.Cell metabolism · 2024Review
- Metabolic hormones are integral regulators of female reproductive health and function.Bioscience reports · 2024Review
- Article
- Induced Pluripotent Stem Cells as a Possible Approach for Exploring the Pathophysiology of Polycystic Ovary Syndrome (PCOS).Stem cell reviews and reports · 2024Review
- A New Approach to Polycystic Ovary Syndrome and Related Cardio-metabolic Risk Factors: Dietary Polyphenols.Current nutrition reports · 2023Review
- Pathophysiological Effects of Contemporary Lifestyle on Evolutionary-Conserved Survival Mechanisms in Polycystic Ovary Syndrome.Life (Basel, Switzerland) · 2023Review
- The physiological functions and therapeutic potential of exosomes during the development and treatment of polycystic ovary syndrome.Frontiers in physiology · 2023Review
- Low-dose spironolactone ameliorates adipose tissue inflammation and apoptosis in letrozole-induced PCOS rat model.BMC endocrine disorders · 2022Article
- Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS).Biomedicines · 2022Review
- A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder among premenopausal women. In addition to infertility, PCOS is associated with insulin resistance, features of the metabolic syndrome, and an increased risk for diabetes. Similar to individuals with metabolic syndrome, many women with PCOS manifest abdominal obesity, suggesting adipose tissue dysfunction. The adipose tissue of women with PCOS is characterized by hypertrophic adipocytes and impairments in lipolysis and insulin action. The expression and secretion of a wide variety of adipokines implicated in insulin resistance, including adiponectin and others, are also altered in PCOS. Collectively, the available data indicate that adipose tissue dysfunction plays a central role in the metabolic abnormalities observed in PCOS. Whether these abnormalities are primary or secondary to hyperandrogenism or other abnormalities in PCOS is not yet known.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.